Fox Chase Cancer Center News

PHILADELPHIA (November 25, 2020)— Five Fox Chase Cancer Center physicians have been named as 2020 Top Docs by Main Line Today. Top Docs were selected by regional physicians from a variety of practices, and the physicians from Fox Chase who were honored cover a range of oncologic specialties.

PHILADELPHIA (November 19, 2020) – Sexually transmitted infections (STIs) have been linked to increased risk for several types of cancer, including prostate cancer. New research out of Fox Chase Cancer Center has shown that a history of STIs combined with a certain single-nucleotide polymorphism (SNP) associated with inflammation decreased risk for prostate cancer among a small group of Jamaican men.

PHILADELPHIA (November 17, 2020)—Results from a recently published study spearheaded by a Fox Chase Cancer Center researcher found that over the last 20 years, research funding provided by the American Head and Neck Society (AHNS) has generated considerable return on investment and achieved the society’s aims of furthering the trajectories of early career researchers.

PHILADELPHIA (November 17, 2020)—Patients with mantle cell lymphoma treated at Fox Chase Cancer Center will now have access to treatment with brexucabtagene autoleucel, also known as Tecartus, the first cell-based gene therapy approved by the Food and Drug Administration (FDA).

PHILADELPHIA (November 16, 2020)—Two leading researchers from Fox Chase Cancer Center are co-authors of the fifth edition of Principles of Virology, the leading virology textbook for undergraduate and graduate students studying how viruses reproduce and cause disease.

PHILADELPHIA (November 13, 2020) – In a recently published paper, researchers at Fox Chase Cancer Center unveiled data that suggested possible new targets for the treatment of T-acute leukemia/lymphoma (T-ALL).

PHILADELPHIA (November 5, 2020) – Researchers at Fox Chase Cancer Center have harnessed the power of the Nobel Prize-winning CRISPR/Cas9 technology to identify cellular factors involved in resistance to sunitinib by clear cell renal cell carcinoma.

PHILADELPHIA (November 4, 2020)—Fox Chase Cancer Center has become the first cancer center in the Northeast to feature a new tumor marker technology that has been described as the next generation of surgical navigation, one that will make breast excisional biopsies and breast-conserving surgeries more precise.